Work

382P Beyond pathologic response: Does spontaneous tumor regression (STR) influence outcomes in resected stage IIIA-N2 non-small cell lung cancer (NSCLC)? A LungART trial substudy

Year: 2025

Type: article

Abstract: In the chemoimmunotherapy era, pathological response to neoadjuvant treatment (NA) has arisen as a surrogate endpoint for survival in resectable NSCLC. However, the prognostic value of STR - described in untreated patients (pts) across multiple tumor types - remains unaddressed. We assessed the impact of viable tumor fraction (VTF) as a marker of STR in resected stage IIIA-N2 NSCLC.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101568

Authors: V.M. Albarran Artahona, M.R. Ghigna, D. Diaz-Jimenez, A. Lopez Gutierrez, W.S. Zrafi, G. Granier, J-P. Dales, V. Westeel, F. Morin, C. Faivre-Finn, M. Guckenberger, R. Reyes, N. Cozic, E. Bouvier, J. Adam, J. Remon Masip, B. Besse, C. Le Pechoux, A. Levy

Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Centre Hospitalier Universitaire de Besançon, Intergroupe Francophone de Cancérologie Thoracique, The Christie Hospital, The Christie NHS Foundation Trust, University of Zurich, University Hospital Zurich, Instituto Oncológico Dr. Rosell, Inserm

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,340

OpenAlex ID: W7117299724

FWCI:

Cites:

Cited by:

Related to: